相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Regulating tumor suppressor genes: post-translational modifications
Ling Chen et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Non-V600E BRAF mutations and EGFR signaling pathway in colorectal cancer
Hiroki Osumi et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency
Mehwish Khaliq et al.
CANCERS (2019)
An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer
Vera E. van der Noord et al.
SCIENTIFIC REPORTS (2019)
Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy
Yanan Li et al.
CANCER BIOLOGY & MEDICINE (2019)
BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
Jaquelyn N. Sanchez et al.
DRUGS (2018)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer
Anuradha Krishnamurthy et al.
CANCER RESEARCH (2018)
Dataset describing the development, optimization and application of SRM/MRM based targeted proteomics strategy for quantification of potential biomarkers of EGFR TKI sensitivity
Shivangi Awasthi et al.
DATA IN BRIEF (2018)
COSMIC: somatic cancer genetics at high-resolution
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2017)
Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
Jeremy C. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
Xu Zhang et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Merope Griffin et al.
ONCOTARGET (2017)
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study
Eiji Shinozaki et al.
BRITISH JOURNAL OF CANCER (2017)
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting
Alastair Greystoke et al.
BRITISH JOURNAL OF CANCER (2017)
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
Zeynep Eroglu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2016)
Epigenetic Changes of EGFR Have an Important Role in BRAF Inhibitor-Resistant Cutaneous Melanomas
Jinhua Wang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)
BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
Francesco Spagnolo et al.
ONCOTARGETS AND THERAPY (2015)
Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth
Melanie Sweetlove et al.
FRONTIERS IN ONCOLOGY (2015)
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma A Randomized Clinical Trial
Richard D. Carvajal et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Phosphoproteomics of MAPK Inhibition in BRAF-Mutated Cells and a Role for the Lethal Synergism of Dual BRAF and CK2 Inhibition
Robert Parker et al.
MOLECULAR CANCER THERAPEUTICS (2014)
BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
Rachel N. Grisham et al.
CANCER (2013)
BRAF mutation is associated with distinct clinicopathological characteristics in colorectal cancer: a systematic review and meta-analysis
C. Clancy et al.
COLORECTAL DISEASE (2013)
ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling
Jeremiah N. Winter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Harboring BRAF Mutations
Antonio Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors
Ildiko Vereczkey et al.
PATHOLOGY & ONCOLOGY RESEARCH (2011)
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Michelle C. Mendoza et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
BRAF inMelanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
Ryan J. Sullivan et al.
JOURNAL OF SKIN CANCER (2011)
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
J. Souglakos et al.
BRITISH JOURNAL OF CANCER (2009)
Down-regulation of the PI3-kinase/Akt pathway by ERK MAP kinase in growth factor signaling
Hideko Hayashi et al.
GENES TO CELLS (2008)
Different effects of point mutations within the B-raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase and nuclear factor κB pathway and cellular transformation
T Ikenoue et al.
CANCER RESEARCH (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
The Raf/MEK/ERK pathway:: new concepts of activation
C Peyssonnaux et al.
BIOLOGY OF THE CELL (2001)
分享论文
